TRVI News and Press, Trevi Therapeutics Inc. From 11/03/21

Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021 Conference Call and Webcast to be Held at 4:30 p.m. ET PR Newswire NEW HAVEN, Conn. , Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc....

Trevi Therapeutics to Present at 11th World Congress on Itch (WCI) PR Newswire NEW HAVEN, Conn. , Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercializ...

Gainers: Nutriband (NTRBW) +84%, Nutriband (OTCQB:NTRB) +38%, Inhibrx (NASDAQ:INBX) +29%, Titan Pharmaceuticals (NASDAQ:TTNP) +14%, Quanterix (NASDAQ:QTRX) +17%. Losers: Organogenesis (NASDAQ:ORGO) -17%, Trevi Therapeutics (NASDAQ:TRVI) -11%,&...

Analysts See Big Upside In These Penny Stocks Whether you’re looking for penny stocks to buy now or ones to add to a watch list, there’s a process involved in finding the best. Of course, a lot will depend on your strategy and outlook on the market. But there are a few bas...

Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re kicking off the week with a look at the biggest pre-market stock market movers for Monday! Source: f11photo/Shutterstock.com There’s plenty of news moving stock today with ...

Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference PR Newswire NEW HAVEN, Conn. , Oct. 7...

Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market Proceeds Will Fund the Development of Haduvio for Severe Chronic Pruritus in Prurigo Nodularis and Chronic Cough in Idiopathic Pulmonary Fibrosis PR Newswire NEW HAVEN, Conn. , Se...

Trevi Therapeutics, Inc. (TRVI) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Bill Forbes - Chief Development Officer Conference Call Participants Serge Belanger - Needham & Company Presentation Opera...

Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Trial Recruiting, Top-Lin...